Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series

Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support f...

Full description

Bibliographic Details
Main Authors:	Sepideh Taghavi, Maryam Chenaghlou, Marzieh Mirtajaddini, Ahmad Amin, Nasim Naderi
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2020-12-01
Series:	Journal of Cardiovascular and Thoracic Research
Subjects:	heart failure stage d angiotensin receptor neprilysin inhibitor inotrope-dependent
Online Access:	https://jcvtr.tbzmed.ac.ir/PDF/jcvtr-12-334.pdf

Similar Items

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor
by: Jingchao Sun, et al.
Published: (2020-09-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Effect of angiotensin receptor neprilysin inhibitor on ventricular remodeling after myocardial infarction in rats
by: Jian An
Published: (2020-11-01)

Neprilysin Inhibitors and Bradykinin
by: Duncan J. Campbell, et al.
Published: (2018-09-01)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
by: Alessandro Bellis, et al.
Published: (2020-11-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Blockade of the Neprilysin and Angiotensin Ameliorates Oxidative Stress in the Cardiovascular Target Tissues of Dexamethasone-induced Hypertensive Rats
by: Duygun Altıntaş Aykan, et al.
Published: (2020-01-01)

Effects of canagliflozin on renal and urinary angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db diabetic mice
by: Thanekar, Unmesha Hemant
Published: (2019)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury
by: Sahmin Lee, et al.
Published: (2021-08-01)

The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis
by: Emil Eik Nielsen, et al.
Published: (2019-10-01)

The immuneregulator role of neprilysin (NEP) in invertebrates
by: E Ottaviani, et al.
Published: (2012-11-01)

The immuneregulator role of neprilysin (NEP) in invertebrates
by: E Ottaviani, et al.
Published: (2012-11-01)

Retracted: Effects of cardiac resynchronization therapy in patients with inotrope‐dependent class IV end‐stage heart failure
by: Ikutaro Nakajima, et al.
Published: (2013-12-01)

Amyloid beta and Alzheimer’s Disease: The role of neprilysin-2 in amyloid-beta clearance
by: Robert eMarr, et al.
Published: (2014-08-01)

The Rationale of Neprilysin Inhibition in Prevention of Myocardial Ischemia-Reperfusion Injury during ST-Elevation Myocardial Infarction
by: Alessandro Bellis, et al.
Published: (2020-09-01)

Breakthrough in Heart Failure therapy: LCZ696 combining ACE-Neprilysin inhibition
by: Sandeep Lahiry
Published: (2017-01-01)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat
by: Javad Habibi, et al.
Published: (2019-03-01)

Effects of Angiotensin II Type 1A Receptor on ACE2, Neprilysin and KIM-1 in Two Kidney One Clip (2K1C) Model of Renovascular Hypertension
by: Laale F. Alawi, et al.
Published: (2021-01-01)

Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2
by: Reza Zolfaghari Emameh, et al.
Published: (2020-06-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-05-01)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
by: Kieran F. Docherty, et al.
Published: (2021-02-01)

Symmetrical peripheral gangrene in sepsis after treatment with inotropes
by: Jiin-Ling Jiang, et al.
Published: (2017-01-01)

Postpartum gangrene of three limbs complicating inotrope therapy: A case report
by: Ahmed S. El-agwany, et al.
Published: (2014-10-01)

Long‐term administration of intravenous inotropes in advanced heart failure
by: Piero Gentile, et al.
Published: (2021-10-01)

Assessment of inotropic and vasodilating effects of milrinone lactate in patients with dilated cardiomyopathy and severe heart failure
by: Edson Antonio Bregagnollo, et al.
Published: (1999-02-01)

A per‐protocol initiation of sacubitril/valsartan in an advanced heart failure disease management programme in the Middle East Gulf Region
by: Bassam Atallah, et al.
Published: (2019-08-01)

Myocardial inotropic reserve: An old twist that constitutes a reliable index in the modern era of heart failure
by: Fragkiskos Parthenakis, et al.
Published: (2016-09-01)

Does glucagon have a positive inotropic effect in the human heart?
by: Jesus Hernández-Cascales
Published: (2018-11-01)

Hypoxia affects neprilysin expression through caspase activation and an APP intracellular domain-dependent mechanism
by: Caroline eKerridge, et al.
Published: (2015-11-01)

Effects of Widespread Inotrope Use in Acute Heart Failure Patients
by: Jeehoon Kang, et al.
Published: (2018-10-01)

Use of Inotropic Agents in Treatment of Systolic Heart Failure
by: Sohaib Tariq, et al.
Published: (2015-12-01)

Inotropic and cardioprotective effects of Daucus carota Linn. on isoproterenol-induced myocardial infarction
by: Pavan Kumar, et al.
Published: (2008-12-01)

Peri-operative Inotrope Use in Off Pump Coronary Artery Bypass Graft Surgeries
by: Nidheesh Chooriyil, et al.
Published: (2017-12-01)

Charakterisierung negativ inotroper Substanzen nach Myokardischämie
by: Stangl, Verena
Published: (2002)